Unlocking AML biology with 5-base whole-genome sequencing: Integrated genomic and epigenomic profiling for biomarker discovery

Acute myeloid leukemia (AML) is characterized by diverse genomic and epigenomic alterations that contribute to disease heterogeneity and biological complexity. Traditional molecular approaches may not fully capture DNA methylation patterns alongside genomic variation within a single workflow. This presentation will explore the research use of 5-base whole-genome sequencing (WGS) to simultaneously generate genomic and methylation data from the same sample.

We will discuss how integrated genomic and epigenomic profiling can be used to investigate AML biology, characterize molecular subtypes, and support the discovery of novel research biomarkers associated with disease progression and treatment response. Research examples will highlight the potential of 5-base WGS to enable deeper biological insights and advance translational research in AML and other hematologic malignancies.

Rashmi Kanagal-Shamanna, MD
Director, Development & Innovation Diagnostics
Professor, Department of Hematopathology
Associate Director, Bone Marrow Laboratory
The University of Texas MD Anderson Cancer Center

This webinar will be recorded on November 11 and will not be streamed live. Register to access the on-demand recording, expected to be available 10–15 business days after the recording date.